AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test

Published by

Mainz Biomed N.V. (NASDAQ: MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the detection and diagnosis of colorectal cancer (CRC). Key attributes of EMERGE that make it superior to mainstream AI and machine learning analytical solutions include its computational speed, ability to handle millions of variables, and ability to operate agnostically without any assumptions or constraints. The partnership expands on Mainz Biomed’s initial deployment of EMERGE for examining the ColoFuture study’s findi…

Read More

See also  Harry Potter star Evanna Lynch: My boyfriend bought me sex toys - I threw them away!

Leave a Reply